As of September 1st, QPS JSW will be headed by Dr. Jaap Wieling, an industry veteran with a broad range of experience including being a co-founder and managing director of what is now QPS Netherlands. Dr. Jaap Wieling will work with JSW founder Dr. Manfred Windisch and JSW's existing staff to help build a bright future for the combined QPS JSW. Dr. Manfred Windisch of JSW will become Chief Scientific Officer – Europe for QPS, and will continue to lead as CEO of JSW Clinical Investigations – a joint alliance company with two other CROs.
QPS provides GLP/GCP-compliant preclinical and clinical research services to pharmaceutical and biotechnology clients worldwide in the areas of Drug Metabolism and Pharmacokinetics, Toxicology, Bioanalysis, Translational Medicine, and Early Stage and Phase II-IV Clinical Research. Founded by Dr. Ben Chien in 1995, QPS has Preclinical Testing and Bioanalysis facilities at its Newark, DE headquarters; and facilities in Groningen, the Netherlands; Taipei, Taiwan; and Hyderabad, India. Early-phase clinical facilities are located in Springfield, MO; Taipei, Taiwan; Groningen, the Netherlands; and Hyderabad, India. Business development offices are maintained throughout the US, Europe, and Asia.
About JSW Life Sciences
JSW is highly experienced and established in both preclinical and clinical service areas and specializes in preclinical services for central nervous system (CNS) diseases. JSW has developed its reputation since 1999 as a full service, high quality CRO and the leading specialist in CNS diseases including Alzheimer's, Parkinson's, Huntington's, stroke, depression, psychosis and schizophrenia. JSW's reputation in the CNS field is further enhanced by its capabilities in preclinical efficacy studies including in vitro mole
|SOURCE QPS, LLC|
Copyright©2012 PR Newswire.
All rights reserved